 DURHAM, N.C., March 01, 2022 GLOBE NEWSWIRE -- Humacyte, Inc. Nasdaq: HUMA, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March. 